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ANALYSES IN GERMANY: RESULTS OF A FEASIBILITY STUDY
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OBJECTIVES: The aim of the review was to evaluate the efﬁcacy and safety of 
imiquimod 5% cream compared with vehicle for treating superﬁcial basal cell carci-
noma. METHODS: The analysis was performed in accordance with the rules of sys-
tematic review, based on the Cochrane Collaboration (Cochrane Reviewer’s 
Handbook) guidelines and the Health Technology Assessment Agency in Poland 
(AOTM) recommendations. RESULTS: Two multicenter, vehicle-controlled, random-
ized clinical trials of high quality were identiﬁed according to predeﬁned selection 
criteria. Treatment with imiquimod 5% cream once a day, 3 times per week resulted 
in signiﬁcantly greater complete response rate than vehicle in the period of 6 as well 
as 12 weeks. Probability of achieving the complete response rate (no histological evi-
dence of superﬁcial basal cell carcinoma in the excised post–treatment target tumor 
tissue) was signiﬁcantly greater for imiquimod 5% cream than vehicle and amounted 
to 18.2 (95% CI: 4.19; 84.84) and 146.14 (95% CI: 69.3; 323.75) respectively at 12 
and 6 weeks after treatment. The incidence of adverse events during the treatment 
period such as application site reaction including itching, pain and tenderness at the 
target tumor site and local skin reaction such as erythema, scabbing, were more fre-
quently recorded in the group of subjects who received imiquimod 5% cream in 
comparison with the vehicle group. CONCLUSIONS: Imiquimod 5% cream appears 
to be effective in the treatment of superﬁcial basal cell carcinoma. A 3 times a week 
dosing demonstrates high efﬁcacy results with acceptable safety proﬁle, during the 6 
as well as 12-week period.
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OBJECTIVES: The inclusion of indirect costs of illness in pharmacoeconomics studies 
is still a subject of considerable debate. The aim of the systematic literature review 
was to present the Polish economic practice concerning indirect costs evaluation of 
health care interventions. Study was conducted as a ﬁrst stage of a research project 
aimed at developing recommendation for methods of calculating indirect cost in 
Poland. METHODS: MEDLINE, EMBASE, Cochrane Library and Polish Medical 
Bibliography (PBL) were searched. Cut-off dates were set to February and March 
2009. The main speciﬁc keywords were ‘indirect costs’ or ‘costs and cost analysis’. 
Extracted data covered; type of study, disease under study, methods for evaluating 
indirect cost, measures of productivity loss value and share in total costs. RESULTS: 
Nineteen studies fulﬁlled the inclusion criteria for this review, of a total of 2300 refer-
ences. Seventeen out of 19 studies were cost of illness studies, 2 were economic analy-
ses. Methods of evaluating indirect costs were all based on human capital approach. 
The work absenteeism unit time measure used to value productivity loss were average 
salary (9/19), Gross Domestic Product (GDP) per capita (7/19), Gross National 
Product per capita (1/19), GDP per active worker (1/19), sold production of industry 
per active worker (1/19). Mean indirect costs amounted to 58% of total costs, with 
a range of 16%-98%. In 5 studies transfer payments (e.g. sick leave) were added to 
productivity loss category. CONCLUSIONS: Indirect cost is rarely included in the 
economic analyses in Poland. Different methods calculating indirect cost limit com-
parison between studies and call for development of robust and widely accepted 
methodology.
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OBJECTIVES: Absenteeism is a major cause of indirect costs of illness. In Poland 
precise data regarding days of work lost due to illness are collected by Social Insurance 
Institution (ZUS). The aim of this study was to estimate absenteeism costs in Poland 
in 2007 based on average monthly gross wages and salaries. METHODS: Human 
capital approach was used to estimate absenteeism costs. We used ZUS and Central 
Statistical Ofﬁce (GUS) data. Average monthly gross wages and salaries estimates were 
calculated taking into consideration sex and province speciﬁc data. The analysis was 
based on an assumption that number of missed days includes only working days (252 
days per year). This assumption was tested within the range of 226 to 365 days (either 
including all calendar days or additionally subtracting 26 days of holidays). Values 
are presented in Euro (exchange rate: 1 Euro  4,50 PLN). RESULTS: Total costs of 
absenteeism in 2007 were estimated to amount of a5.3 billion (range a3.7–a5.9 
billion). In Silesia province the cost of day of sickness absence estimated per person 
employed was nearly twice as high as in Podlaskie province. Total costs of absenteeism 
calculated based on GDP per capita were similar, however there were some differences 
among territory speciﬁc estimations. Cost data based on GDP per capita or average 
monthly gross wages were approximately twice as high as ZUS data on the amount 
of funds spent on sick pay. CONCLUSIONS: Given that several predictors of sickness 
absence are not accounted to GDP per capita or average monthly gross wages and 
salaries based estimation, it seems that ZUS data on amount of mean sick pay may 
provide a reliable tool for absenteeism costs estimation in Poland.
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Economic evaluation requires identiﬁcation and measurement of resources from 
various viewpoints (patient, hospital, health insurance, society). Although the hospital 
resources are easily identiﬁed, resources such as travel expenses or loss of productivity 
are often more difﬁcult to measure or valorize. OBJECTIVES: To identify these 
various costs or cost determinants and specify for whom, for what and where they 
can be found in order to construct a standard costs toolkit including source data and 
costs per patient. METHODS: A check-list of costs items from various viewpoints has 
been established. Two approaches were combined: 1) The ﬁrst consisted of detailed       
examination of freely available databases, data derived from national institute or 
ministry websites, this ﬁrst step has been realized, and 2) The second consisted of 
analyzing costs or parameters usually difﬁcult to estimate. We tried to quantify these 
costs items. RESULTS: The various items and the various possible types of measure-
ments were listed. In the example of loss of productivity related to sick leave of a 
cancer patient, several parameters are required in order to perform the calculation by 
type of cancer. Gross domestic product is the starting point to determine the added 
value generated by an actively employed individual. We then calculated the mean 
added value of an actively employed individual (a3800 per month) and took the mean 
duration of sick leave of 120 days into account. Losses of productivity are estimated 
by cancer site and are about a1900 per incident patient and per year. According to 
national health insurance and survey on national thirty long-term diseases, travel 
expenses are about a500 on average per cancer patient and per year. CONCLUSIONS: 
Making a standard cost toolkit available could improve and foster the economic 
assessment processes in France.
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OBJECTIVES: Good quality health economic (HE) analysis could be an important 
tool in guiding (cost) efﬁciency in health care development in China. To review HE 
analyses from China and assessing their quality using a standardised questionnaire. 
METHODS: Search of MEDLINE and EMBASE (1964–2008) using key words:         
China, cost-utility analysis (CUA), cost-effectiveness analysis (CEA), cost-minimisation 
analysis (CMA), cost-beneﬁt analysis (CBA), and cost analysis (CA). Included were 
original HE evaluations examining a (medical) treatment/programme in a Chinese 
setting (including Hong Kong and Taiwan) describing costs and/or consequences in 
English or Chinese language. Quality was independently assessed by 4 raters using a 
13 items checklist derived from previously published HE assessments. Obtainable 
scores were 0 (“Incorrect”), 1 (“Not Reported”), 2 (“Doubtful”), 3 (“Acceptable”), 
4 (“Correct”) or N/A if not applicable. Post-hoc analyses were carried out to determine 
a time trend in quality or whether the observed differences in quality scores between 
languages existed. RESULTS: 36 articles were included for assessment: 17 CEAs, 7 
CBAs, 7 CUAs, and 5 CAs. No article used CMA. Majority of the evaluations was 
conducted in mainland China (64%), 31% in Hong Kong, and 5% in Taiwan. Mean 
quality score of all articles was ‘Acceptable’ (mean  3.1; SD  0.58) ranging from 
2.0–4.0. Post hoc analyses demonstrated that English publications had a signiﬁcant 
higher (; p  0.0005, Mann-Whitney U test) quality (mean  3.5; SD  0.45) compared 
to Chinese (mean  2.8; SD  0.46). No signiﬁcant time trend existed. CONCLU-
SIONS: HE analyses from China were considered ‘Acceptable’ and their quality was 
similar to previous assessments. Post-hoc analysis suggested a signiﬁcant difference 
between analyses published in English compared to Chinese. This study’s major limita-
tion is that low quality scores may be caused by poor reporting rather than poor 
research. Further research is needed to determine the underlying reasons of the quality 
and examine the impact of analyses on decision-making.
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OBJECTIVES: The indirect costs seem to be a relevant part of a total cost of illness, 
although there is no consensus whether they should be included in pharmacoeconomic 
analysis or which methods of calculations should be used. The aim of the survey was 
to collect data on practice and preferences of decision-makers and experts in health 
economics concerning the role and methods of calculating indirect costs in Poland. 
METHODS: The questionnaire contained 18 questions covering the need for indirect 
